ObsEva SA

General Information

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We are advancing a pipeline of orally-administered innovative new chemical entities, or NCEs, for the treatment of symptoms associated with endometriosis and uterine fibroids, improvement of clinical pregnancy and live birth rates in women undergoing in vitro fertilization, or IVF, and treatment of preterm labor.

Employees: 27
Founded: 2012
Contact Information
Address Chemin des Aulx, 12 1228 Plan-les-Ouates, Geneva, Switzerland
Phone Number +41 22 552 38 40
Web Address https://www.obseva.com
View Prospectus: ObsEva SA
Financial Information
Market Cap $444.5mil
Revenues $0.04 mil (last 12 months)
Net Income $-25.6 mil (last 12 months)
IPO Profile
Symbol OBSV
Exchange NASDAQ
Shares (millions): 6.5
Price range $15.00 - $15.00
Est. $ Volume $96.8 mil
Manager / Joint Managers Credit Suisse/ Jefferies/ Leerink Partners
CO-Managers -
Expected To Trade: 1/26/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change